Dr Gang Zhang, PhD - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Dr Gang Zhang

PhD

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Los Angeles, California | United States

Main Specialties: Chemistry

Additional Specialties: Medicinal Chemistry

ORCID logohttps://orcid.org/0000-0003-0774-5710

Dr Gang Zhang, PhD - Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Dr Gang Zhang

PhD

Introduction

Primary Affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Los Angeles, California , United States

Specialties:

Additional Specialties:

Research Interests:

Education

Aug 2008 - Jul 2011
Peking Union Medical College
Ph.D.
Medicinal Chemistry
Sep 2004 - Jul 2007
Shenyang Pharmaceutical University
M.S.
Medicinal Chemistry

Experience

Mar 2019
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
May 2016 - May 2016
Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Materia Medica
Research Associate Professor
Medicinal Chemistry
Feb 2012 - Feb 2012
Virginia Commonwealth University
Postdoctoral Associate Researcher
Medicinal Chemistry

Publications

10Publications

200Reads

2Profile Views

17PubMed Central Citations

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.

Viruses 2018 11 30;10(12). Epub 2018 Nov 30.

Department of Microbiology and Immunology, College of Medicine, The University of Illinois at Chicago, Chicago, IL 60612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v10120678DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315506PMC
November 2018
61 Reads
3.279 Impact Factor

Virtual Screening of Small Molecular Inhibitors against DprE1.

Molecules 2018 Feb 27;23(3). Epub 2018 Feb 27.

Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University Jinming Campus, Kaifeng 475004, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23030524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017230PMC
February 2018
5 Reads
2.420 Impact Factor

A direct, ratiometric, and quantitative MALDI-MS assay for protein methyltransferases and acetyltransferases.

Anal Biochem 2015 Jun 14;478:59-64. Epub 2015 Mar 14.

Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA 23219, USA; Institute for Structural Biology and Drug Discovery, Virginia Commonwealth University, Richmond, VA 23219, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2015.03.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855292PMC
June 2015
27 Reads
2 Citations
2.220 Impact Factor

Kinetic mechanism of protein N-terminal methyltransferase 1.

J Biol Chem 2015 May 14;290(18):11601-10. Epub 2015 Mar 14.

From the Department of Medicinal Chemistry, the Institute for Structural Biology and Drug Discovery, and

View Article

Download full-text PDF

Source
http://www.jbc.org/content/290/18/11601.full.pdf
Web Search
http://www.jbc.org/lookup/doi/10.1074/jbc.M114.626846
Publisher Site
http://dx.doi.org/10.1074/jbc.M114.626846DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416863PMC
May 2015
44 Reads
6 Citations
4.573 Impact Factor

Design, synthesis, and kinetic analysis of potent protein N-terminal methyltransferase 1 inhibitors.

Org Biomol Chem 2015 Apr 25;13(14):4149-54. Epub 2015 Feb 25.

Department of Medicinal Chemistry, and the Institute of Structural Biology & Drug Discovery, Virginia Commonwealth University, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c5ob00120jDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857722PMC
April 2015
24 Reads
6 Citations
3.562 Impact Factor

Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.

Evid Based Complement Alternat Med 2014 16;2014:958937. Epub 2014 Apr 16.

The First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/958937DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009204PMC
May 2014
29 Reads
3 Citations
1.880 Impact Factor

Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.

J Med Chem 2012 Oct 20;55(19):8409-17. Epub 2012 Sep 20.

J. Med. Chem.

Clofazimine (CFZ), a member of the riminophenazine class, has been studied in clinical trials for the treatment of multidrug-resistant tuberculosis (MDR-TB). CFZ has several side effects which can be attributed to its extremely high lipophilicity. A series of novel riminophenazine analogues bearing a C-2 pyridyl substituent was designed and synthesized with the goal of maintaining potent activity against Mycobacterium tuberculosis (M. tuberculosis) while improving upon its safety profile by lowering the lipophilicity. All compounds were evaluated for their in vitro activity and cytotoxicity. The results demonstrated that many new compounds had potent activity against M. tuberculosis with MICs of less than 0.03 μg/mL and low cytotoxicity with IC(50) values greater than 64 μg/mL. Some compounds were tested for in vivo efficacy against MDR-TB in an experimental mouse infection model. Two compounds demonstrated equivalent or better efficacy than CFZ in this model with significantly reduced skin discoloration potential.

View Article
October 2012
10 Reads

Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis.

Molecules 2012 17;17(4):4545-59. Epub 2012 Apr 17.

Molecules

Clofazimine, a member of the riminophenazine class of drugs, is the cornerstone agent for the treatment of leprosy. This agent is currently being studied in clinical trials for the treatment of multidrug-resistant tuberculosis to address the urgent need for new drugs that can overcome existing and emerging drug resistance. However, the use of clofazimine in tuberculosis treatment is hampered by its high lipophilicity and skin pigmentation side effects. To identify a new generation of riminophenazines that is less lipophilic and skin staining, while maintaining efficacy, we have performed a systematic structure-activity relationship (SAR) investigation by synthesizing a variety of analogs of clofazimine and evaluating their anti-tuberculosis activity. The study reveals that the central tricyclic phenazine system and the pendant aromatic rings are important for anti-tuberculosis activity. However, the phenyl groups attached to the C2 and N5 position of clofazimine can be replaced by a pyridyl group to provide analogs with improved physicochemical properties and pharmacokinetic characteristics. Replacement of the phenyl group attached to the C2 position by a pyridyl group has led to a promising new series of compounds with improved physicochemical properties, improved anti-tuberculosis potency, and reduced pigmentation potential.

View Article
April 2012
7 Reads

Synthesis of new riminophenazines with pyrimidine and pyrazine substitution at the 2-N position.

Molecules 2011 Aug 16;16(8):6985-91. Epub 2011 Aug 16.

Department of Medicinal Chemistry, Beijing Key Laboratory of Active Substance Discovery and Drugability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules16086985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264567PMC
August 2011
10 Reads
2.420 Impact Factor

Top co-authors

Rong Huang
Rong Huang

State Key Laboratory of Freshwater Ecology and Biotechnology

3
Darrell L Peterson
Darrell L Peterson

Virginia Commonwealth University

2
Pahul Hanjra
Pahul Hanjra

Virginia Commonwealth University

2
Yunfei Mao
Yunfei Mao

the Institute for Structural Biology and Drug Discovery

2
Stacie L Richardson
Stacie L Richardson

Virginia Commonwealth University

2
Zhenyu Qiu
Zhenyu Qiu

the First Affiliated Hospital

1
Dun Zhou
Dun Zhou

Heinrich Heine-University

1
Shuman Yang
Shuman Yang

Garvan Institute of Medical Research

1
Lei Tian
Lei Tian

Massachusetts Institute of Technology

1
Hongxia Yuan
Hongxia Yuan

Shenyang Pharmaceutical University

1